remdesivir - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.01 [0.02, 51.30]< 10%1 study (1/-)49.7 %lownot evaluable highcrucial-
deaths 1.01 [0.02, 51.30]< 10%1 study (1/-)49.7 %lownot evaluable highcrucial-
hospitalization or death 0.13 [0.03, 0.58]< 10%1 study (1/-)99.6 %lownot evaluable highcrucial-
hospitalization 0.28 [0.10, 0.77]< 10%1 study (1/-)99.3 %lownot evaluable highimportant-

safety endpoints 00

AE leading to drug discontinuation 0.40 [0.08, 2.09]< 10%1 study (1/-)86.0 %lownot evaluable highimportant-
serious adverse events 0.25 [0.09, 0.69]< 10%1 study (1/-)99.6 %lownot evaluable highimportant-
adverse events 0.85 [0.61, 1.19]< 10%1 study (1/-)83.0 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.